Hepatitis B Management Guidelines

Universal Screening and Monitoring

The American Gastroenterological Association recommends that all adults aged ≥18 years should undergo hepatitis B screening at least once in their lifetime using a three-test panel: HBsAg, anti-HBc, and anti-HBs 1
For patients anticipating immunosuppressive therapy or chemotherapy, screening must occur prior to or at the beginning of treatment, but therapy should not be delayed for test results, as recommended by the American Society of Clinical Oncology 2, 3, 4
Patients with chronic HBV who are not treatment candidates require regular monitoring with ALT and HBV DNA levels, according to the American Association for the Study of Liver Diseases 1, 5

Monitor ALT every 3-6 months and HBV DNA every 6-12 months for patients with chronic HBV infection, as suggested by the European Association for the Study of the Liver 5, 6
HBeAg/anti-HBe status should be checked annually for patients with chronic HBV infection, as recommended by the American Association for the Study of Liver Diseases 6
For patients over age 40 with persistently elevated HBV DNA or intermittent ALT elevations, treatment should be strongly considered as they face increased risk of cirrhosis and hepatocellular carcinoma, according to the American Gastroenterological Association 5

The American Association for the Study of Liver Diseases recommends HCC surveillance with ultrasound every 6 months for high-risk patients, including Asian men >40 years old, Asian women >50 years old, patients with cirrhosis, and patients with family history of HCC 5
Combine ultrasound with alpha-fetoprotein (AFP) testing every 6 months, as these modalities are complementary, according to the European Association for the Study of the Liver 5

Patients at high risk of HBV reactivation should receive antiviral prophylaxis regardless of HBsAg status, including those receiving anti-CD20 monoclonal antibodies, hematopoietic stem cell transplantation, CAR-T cell therapy, or high-dose corticosteroids, as recommended by the American Society of Clinical Oncology 1, 2, 7
For high-risk patients, prophylaxis should continue during therapy and for at least 12 months after completion, according to the American Society of Clinical Oncology 7, 3, 8

For patients receiving antiviral prophylaxis during immunosuppression, monitor ALT and HBV DNA at baseline and every 6 months during therapy, as recommended by the American Society of Clinical Oncology 2, 4, 10
Monitoring frequency increases to every 1-3 months for patients on monitoring-only strategies, according to the American Gastroenterological Association 1, 3